Last updated 6 days ago

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

526 patients around the world

Available in Chile

Sanofi

526Patients around the world

This study is for people with

Kidney Transplant

Requirements for the patient

To 70 Years

All Gender

Medical requirements

: Participants who are scheduled to receive their first kidney transplant from a living or deceased donor.
Participants with low to moderate immunological risk.

: Deceased donor kidney graft qualified as expanded criteria donor or donor after cardiac death.
Positive T or B cell crossmatch, or positive virtual crossmatch per local practice at screening.
Participants receiving a kidney graft from HLA-identical living-related donors, or have current or previous solid organ, cell, or multi-organ transplantation, or paired kidney transplantation.
Participants whose primary causes of ESKD are idiopathic FSGS, C3 glomerulopathy, lupus nephritis, or thrombotic microangiopathy.
Evidence of active or latent TB, HIV, HBV or HCV infection.
Participants who have known genetically predisposed thrombophilia, have history of thromboembolic events, or who need long-term anti-coagulation therapy.
Participants who have severe medical co-morbidities, active infection, or severely limited life expectancy due to underlying medical conditions that are generally precluded from kidney transplant.

StudyFREXERA

SponsorSanofi

Study typeInterventional

Conditions

Kidney Transplant

Requirements

To 70 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT07412470